IDEAYA Biosciences Announces Upcoming Investor Events, Darovasertib Trial Update

Company provides guidance on timing of topline data release from Phase 2/3 OptimUM-02 trial in metastatic uveal melanoma

Mar. 22, 2026 at 2:06pm

Got story updates? Submit your updates here. ›

IDEAYA Biosciences, a precision medicine oncology company, announced its participation in upcoming investor relations events and provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2*-negative metastatic uveal melanoma. The company expects the database lock in the first half of April, followed by the topline data analysis thereafter.

Why it matters

The upcoming topline data from the OptimUM-02 trial is highly anticipated, as it will provide key insights into the efficacy of IDEAYA's lead oncology candidate, darovasertib, in treating a rare and aggressive form of eye cancer. The results could potentially support the further development and regulatory approval of this targeted therapy.

The details

IDEAYA Biosciences will host a live investor and analyst webcast to discuss the topline results from the OptimUM-02 trial. The company will also participate in two investor conferences in May 2026, where its CEO will present and host fireside chats.

  • The database lock for the OptimUM-02 trial is projected in the first half of April 2026.
  • Topline data analysis from the OptimUM-02 trial will be released shortly after the database lock.
  • The investor and analyst webcast to discuss the topline results will be held following the data release.
  • IDEAYA will present at the Bank of America Merrill Lynch Health Care Conference on May 12, 2026.
  • IDEAYA will present at the Stifel 2026 Targeted Oncology Virtual Forum on May 19, 2026.

The players

IDEAYA Biosciences, Inc.

A precision medicine oncology company committed to the discovery and development of targeted therapeutics.

Yujiro S. Hata

President and Chief Executive Officer of IDEAYA Biosciences.

Laura Prendergast

Managing Director, PhD at Stifel.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.